Psilocybin With Intracranial Neural Sensing

Part of paid clinical trials in San Francisco, California.

Sponsor
Joshua Woolley, MD, PhD
Study ID
NCT06919640
Phase
PHASE1
Status
Enrolling By Invitation

Conditions

  • Chronic Pain

Eligibility Criteria

Sex
ALL
Age
21 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Psilocybin — DRUG
    10mg oral psilocybin

Study Details

This is an open-label, single-arm, pilot study exploring the neural, sensory, and cognitive effects of a single, medium dose of psilocybin in patients with chronic pain who already have implanted sensing-capable deep brain stimulation (DBS) devices. Outcomes include multi-site neural recording from previously placed ambulatory sensing-capable DBS devices, quantitative sensory and cognitive testing, and self-reports of pain. We hypothesize that psilocybin will change functional connectivity, decrease clinical and task-based pain reports, and improve cognitive functions.

Key Dates

Start date
Jun 1, 2025
Status verified
Apr 2025
Primary completion
Apr 30, 2028
Completion
Apr 30, 2028

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: 10mg oral psilocybin

Primary Outcome Measure

Changes in neural functional connectivity [ Time Frame: Drug administration to 90 days following ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94143-

Find similar trials in San Francisco, CA

By research site
University of California, San Francisco· San Francisco, CA

Related Studies